Soligenix Inc. (NASDAQ: SNGX) announced results from the third cohort of its Phase 2a trial testing SGX302, a synthetic hypericin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE